TechFlow news, on July 1, Hong Kong-listed company Navigator Biotech Limited (00399) announced the signing of a memorandum of understanding to plan the acquisition of all shares in a target company, subject to the condition that the target company completes its acquisition of Conflux blockchain-related assets. The consideration for the acquisition will be paid in cash, company shares, or convertible bonds, with the specific amount to be determined. The memorandum of understanding is valid for 12 months, during which the seller is prohibited from negotiating the target company's equity with any third party. This move aims to help Navigator Biotech expand its blockchain technology business, achieve business diversification, and identify new profit growth opportunities. The transaction will only be finalized upon the signing of a formal agreement.
Risk Disclosure: This website's content is not investment advice and offers no trading guidance or related services. Per regulations from the PBOC and other authorities, users must be aware of virtual currency risks. Contact us / support@techflowpost.com ICP License: 琼ICP备2022009338号
